DAY 1 - Friday, February 3, 2012
Welcome
Glaucoma 360: 3-day event promises all-encompassing view
San Francisco—Ophthalmology Times welcomes attendees of this weekend’s Glaucoma 360 for a “full-compass view” of the cure, catalysts, and care of glaucoma, Feb. 2 to 4.
Three separate events—uniting research, industry, and philanthropy to find a cure for glaucoma—are planned for this gathering, which is presented by the Glaucoma Research Foundation (GRF), a national nonprofit organization dedicated to finding a cure for glaucoma, in association with Ophthalmology Times. All activities for the meeting will be held at the Palace Hotel.
“Glaucoma 360 promises to bring together a confluence of top-tier glaucoma leaders from the fields of medicine, science, business, investment, philanthropy, and media with those affected by glaucoma. All proceeds will benefit [GRF] and help support research, outreach, and education,” said Andrew Iwach, MD, chairman of GRF’s board of directors, and Adrienne Graves, PhD, a member of GRF’s board of directors. The two are co-chairing the event.
Ophthalmology Times is the global media sponsor and official publication for Glaucoma 360 events. » MORE
Catalyst for a Cure
CFC research poised for a promising future
San Francisco—Catalyst for a Cure (CFC) was launched a decade ago as a novel initiative to advance basic science research on the pathophysiology of glaucoma, ultimately to lead to a cure.
At Catalyst for a Cure: The Annual Benefit on Thursday evening, the four principal investigators provided an update on their progress in elucidating the molecular mechanisms of neurodegeneration in glaucoma and identifying promising targets for therapeutic interventions that can delay or prevent retinal ganglion cell loss. » MORE
Second CFC team gears up for ambitious goal
San Francisco—Encouraged by the successes of the first Catalyst for a Cure (CFC) research team, the Glaucoma Research Foundation (GRF) is now funding a second team of scientists charged with identifying specific and sensitive biomarkers that can improve the diagnosis and management of glaucoma.
At Catalyst for a Cure: The Annual Benefit on Thursday evening, principal investigators in the group expressed their excitement about working in the innovative, collaborative research model and the opportunity to apply the talents and expertise of their individual laboratories to achieve their clinically important goal. » MORE
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
